source
- Compass Therapeutics to file BLA for tovecimig despite FDA call for new trialCompass Therapeutics announced it will continue pursuing a biologics license application (BLA) for its bispecific antibody tovecimig aimed at advanced biliary tract cancer, even after the FDA sugge…
- Novo Nordisk may secure more favorable terms under Medicare’s Bridge obesity drug programNovo Nordisk and Eli Lilly have been profiting from a Medicare pilot that caps obesity drug prices for seniors at $245 a month. Recent analysis suggests Novo could negotiate an even better arrangem…